Results 121 to 130 of about 106,545 (283)

Design, Synthesis, and In Silico Insights of new 4‐Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines

ChemistryOpen, EarlyView.
A novel series of hybrid 4‐(4‐benzoylpiperazin‐1‐yl)‐6‐nitroquinoline‐3‐carbonitrile derivatives has been designed, synthetized and evaluated for anticancer properties on the NCI60 panel. Strong antiproliferative effects have been detected against renal cancer cells.
Gabriele La Monica, Alessia Bono, Federica Alamia, Annamaria Martorana, Antonino Lauria   +4 more
wiley   +1 more source

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

Haematologica, 2008
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease.
Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster   +5 more
doaj   +1 more source

Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies

The Journal of Pathology, EarlyView.
Abstract Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms,
Larissa E Vlaming‐van Eijk, Guolu Tang, Arno R Bourgonje, Wilfred F A den Dunnen, Jan‐Luuk Hillebrands, Harry van Goor   +5 more
wiley   +1 more source

Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells

Research in Pharmaceutical Sciences, 2017
Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 ...
Somayeh Atari-Hajipirloo, Saba Nikanfar, Amir Heydari, Fatemeh Kheradmand   +3 more
doaj   +1 more source

Desmoid‐Type Fibromatosis Tumors in Children After First‐Line Failure: Clinical Aspects and Approaches for Subsequent Therapeutic Lines

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Desmoid‐type fibromatosis (DTF) is a rare intermediate malignancy with high local aggressiveness and recurrence in children after first‐line methotrexate‐vinblastine (Mtx‐Vbl) regimen. The objective is to describe refractory DTF to standardize second‐line therapy.
Anna Borovkov, Daniel Orbach, Jacinthe Bonneau‐Lagacherie, Lina Carausu, Grégory Guimard, Stéphanie Haouy, Sarah Jannier, Anne Pagnier, Stéphanie Proust, Cécile Verite, Marie Pierre Castex, Yves Reguerre, Pascale Blouin, Ludovic Mansuy, Lucy Métayer, Nadège Corradini, Anne Sophie Defachelles, Hélène Boutroux   +17 more
wiley   +1 more source

Imatinib for chronic myeloid leukaemia: a NICE mess [PDF]

, 2001
Stephen G O'SBrien
openalex   +1 more source

Thiostrepton Suppresses the Progression of Rhabdomyosarcoma by Inhibiting the PI3K‐AKT Signaling Pathway

Pediatric Discovery, EarlyView.
The study establish TST as a multi‐mechanism PI3K‐AKT inhibitor for refractory RMS while validating Cmap‐driven drug repurposing for pediatric oncology. ABSTRACT Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma with 5‐year survival below 30% in high‐risk/metastatic cases, was investigated through integrated bioinformatics analysis (
Yu Wang, Peng Hong, Zhiqiang Gao, Wei Ma, Zaihong Hu, Jie Lin, Kongkong Cui, Qinlin Shi, Xiao‐Mao Tian, Guanghui Wei   +9 more
wiley   +1 more source

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta [PDF]

, 2002
Jane F. Apperley, Martine Gardembas, Junia V. Melo, R. Russell‐Jones, Barbara J. Bain, E. Joanna Baxter, Andrew Chase, Judith M. Chessells, Marie Colombat, Claire Dearden, Saša Dimitrijević, François-X. Mahon, David Marin, Zariana Nikolova, Eduardo Olavarría, Sandra Silberman, Beate Schultheis, Nicholas C.P. Cross, John M. Goldman   +18 more
openalex   +1 more source

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

Journal of Experimental & Clinical Cancer Research, 2009
Background Imatinib, a tyrosine kinase inhibitor currently approved for treatment of several malignancies, has been shown to be a substrate for multiple efflux-transporter proteins, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
Sparreboom Alex, Figg William D, Smith Nicola F, Gardner Erin R   +3 more
doaj   +1 more source

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias [PDF]

, 2002
Oliver G. Ottmann, Brian J. Druker, Charles L. Sawyers, John M. Goldman, J Reiffers, Richard T. Silver, S Tura, Thomas Fischer, Michael W. Deininger, Charles A. Schiffer, Michele Baccarani, Aloïs Gratwohl, Andreas Hochhaus, Dieter Hoelzer, Sofia Fernandes‐Reese, Insa Gathmann, Renaud Capdeville, Stephen G. O’Brien   +17 more
openalex   +1 more source